Skip to main content

Table 4 Predicted recruitment per site and timeline

From: Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales (“MERINO-3”): study protocol for a multicentre, open-label randomised non-inferiority trial

# Sites

Per month

Per annum

1

13.1

157.5

10

1.3

15.7

15

0.9

10.5

20

0.7

7.9

25

0.5

6.3

30

0.4

5.2

35

0.4

4.5

40

0.3

3.9

Back to article page

Trials

ISSN: 1745-6215